Ro 25-6981

Ro 25-6981 is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 has the potential for the research of parkinson's disease (PD) [1][2][3].

Product Specifications

CAS Number

[169274-78-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

IGluR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ro-25-6981.html

Purity

99.55

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC1=CC=C([C@H](O)[C@@H](C)CN2CCC(CC3=CC=CC=C3)CC2)C=C1

Molecular Formula

C22H29NO2

Molecular Weight

339.47

Precautions

H302, H315, H319, H335

References & Citations

[1]Löschmann PA, et al. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol. 2004 May;187 (1) :86-93.|[2]Szczurowska E, et al. Different action of a specific NR2B/NMDA antagonist Ro 25-6981 on cortical evoked potentials and epileptic afterdischarges in immature rats. Brain Res Bull. 2015 Feb;111:1-8. |[3]Jiang M, et al. Antinociception and prevention of hyperalgesia by intrathecal administration of Ro 25-6981, a highly selective antagonist of the 2B subunit of N-methyl-D-aspartate receptor. Pharmacol Biochem Behav. 2013 Nov;112:56-63.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

NMDA Receptor

Citation 01

Cell Death Differ. 2023 Jul;30 (7) :1726-1741.|CNS Neurosci Ther. 2023 May;29 (5) :1229-1242.|Exp Brain Res. 2023 Dec;241 (11-12) :2735-2750.|Neurobiol Dis. 2025 Oct 15:215:107090.|Neuropharmacology. 2022 Mar 15:206:108947.|Neurochem Int. 2021 Feb:143:104942.|Sci Rep. 2022 Oct 12;12 (1) :17114.